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median total interval and median treatment interval as 
cutoff points to divide patients. Univariable and 
multivariable Cox proportional hazard model was used to 
evaluate overallsurvival (OS).  
 
 
 
Results: At a median follow up of 37 months, the 3-year OS 
for the entire cohort was 63%. Median total interval and 
treatment interval were of 98 days and 29 days, respectively. 
Patients with longer total interval were more likely to be 
patients with a low comorbidity grade (ACE-27 grade 0-1). On 
multivariable analysis a longer total interval was associated 
with a reduced risk of dying (hazard ratio 0.37, 95% CI 0.13 – 
1,01; p = 0.05). No association of longer treatment interval 
with OS was noted on univariable and multivariable analysis. 
Longer treatment interval resulted associated with the use of 
PET for staging (p = 0.13), and with the use of CCRT for 
treatment (p = 0.05). In the subgroup analysis by treatment 
modality, no difference in OS according to treatment interval 
was noted. 
 
Conclusion: In HNSCC patients with stage III-IV at diagnosis, a 
reduction of total interval and of treatment delay does not 
ameliorate survival. Development of fast track referral 
strategies should be aimed at increasing the ratio of stage I-II 
patients. 
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Purpose or Objective: In head and neck cancer absolute 
improvements in locoregional control rate and overall 
survival rate are achieved when radiotherapy is accelerated. 
Concurrent chemotherapy also have been used to improve 
outcomes at the cost of increased toxicity. The use of IMRT 
for head and neck cancer has been associated with reduced 
acute toxicity. Clinical experience with accelerated IMRT-SIB 
with concurrent chemotherapy for advanced oropharyngeal 
squamous cell carcinoma (LAOC), however, is limited. 
Objective of our study is to evaluate efficacy and toxicity of 
an accelerated hypofractionated SIB-IMRT with Tomotherapy 
and concurrent chemotherapy in LAOC. 
 
Material and Methods: Between July 2009 and February 
2014, 59 consecutive patients with LAOC received 
accelerated hypofractionated radiotherapy with tomotherapy 
and concurrent chemotherapy. The disease was stage III in 8% 
and stage IVa in 92% of patients. Prescribed doses to primary 
tumor and involved nodes was 66 Gy at 2,2 Gy/fraction, high 
risk and low risk nodes received simultaneously 60 Gy and 54 
Gy at 2,0 Gy and 1,8 Gy/fraction, over 6 weeks. Acute 
toxicity was scored according to RTOG and late toxicity 
according to CTCAE-4 criteria. The disease free survival 
(DFS), local disease free survival (local-DFS), metastasis free 
survival (MFS) and overall survival were calculated using the 
Kaplan-Meier method. 
 
Results: With median follow-up of 38 months (range 14-70) 
the estimated 3-years local-DFS rate, MFS, DFS and OS were 
88%±0.04SE, 91%±0.04SE, 82%±0.05SE, and 83%±0.04SE, 
respectively. The complete response rate was 88%. All the 
patients completed the radiotherapy; the median treatment 
duration was 43 days, six patients have temporarily 
discontinued treatment (median: 5 days) because of toxicity. 
No grade 4 acute toxicitiy was observed, maximal acute 
toxicities were G3: mucosa 31%, skin 15%, dysphagia 24%, 
leukopenia 5%. Maximal late toxicities were: xerostomia G2 
36%, mucosa G2 23%, skin G2 12%, laryngeal G2 17%, 
dysphagia G2 14%, osteoradionecrosis 3%, trismus 9%. 
 
Conclusion: This analysis shows that a moderatly accelerated 
hypofractionated IMRT-SIB in tomotherapy and concurrent 
chemotherapy achieved high tumor local control and 
acceptable toxicity compared with previous 
chemoradiotherapy treatment with standard fractionation. 
Based on these results we elaborate a randomized clinical 
trial with a more hypofractionated regimen in order to obtain 
a better local control without increasing toxicity. 
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Purpose or Objective: Overall treatment time (OTT) is an 
important factor in head and neck radiotherapy of squamous-
cell carcinoma, the authors investigate its role in a 
nasopharyngeal carcinoma (NPC) population. 
 
Material and Methods: We reviewed 109 patients charts with 
NPC. Pathological, clinical and dosimetric data were 
retrieved. All patients received concomitant chemo-radiation 
(CCRT) with IMRT-SIB with 69.96Gy to GTVs, 59.4 and 54Gy to 
CTVs in 33 fractions (RTOG0615). Cisplatin-based 
chemotherapy (CT) was prescribed as per Intergoup 0099. 
OTT was recorded from the first day of radiation through the 
last day of CCRT regardless adjuvant CT. Per protocol 
treatment was defined as OTT < 7 weeks. Any interruption 
was recorded as well its length and cause. Kaplan-Meier 
curves were created by SPSS (IBM Statistics), log-rank test 
was applied to detect differences and Cox regression model 
was adjusted to compare variables. 
 
Results: From 109 patients, median age was 53; 74% male; 
71% were WHO grade III; 43% T1; 14% T2; 18% T3, 25% T4; 17% 
N0; 17% N1; 39% N2; 27% N3. With a median follow up of 22 
months, 2-year local control was 95,9%, freedom from 
metastases was 88% and overall survival was 79,8%. 9 
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patients were excluded because didn't receive CT (T1N0). 
From the remaining 100, 95 received concomitant plus 
adjuvant CT and 5 concurrent CT. We found a median OTT of 
49 days (range: 11-83 days). 39 patients completed CCRT in 
more than 7 weeks (50-83 days) from which 31 (79%) in 8 
weeks and the remaining 8 (21%) in more than 8 weeks. 
Interruption causes were by medical indication in 6 (15%), 
and non-clinical reasons in 33 (85% - patient no show, 
machine breakdown, and mis-coordination between 
departments). Compensations were performed at the 
discretion of the treating physician in the 8 patients with OTT 
longer than 8 weeks. No difference in local control (LC, p= 
0.766), overall survival (OS, p=0.855) or metastases free 
survival (p= 0.131). Cox regression confirmed age, N stage, 
local control and distant metastases status as prognostic 
factors however no impact was found for OTT (p = 0.890 for < 
7 weeks; p = 0.959 for < 8 weeks; and p = 0.960 for > 8 
weeks). 
 
 
Conclusion: In our study, we found no differences in LC and 
OS regardless OTT. These data must be interpreted with 
caution due to the high number of patients receiving CT that 
may compensate the unplanned interruptions in such a 
sensitive entity. Further studies with longer follow up are 
necessary to recommend or not withholding compensations in 
this setting. 
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Purpose or Objective: There have been numerous studies 
that have shown the importance of tumor volume as an 
independent prognostic factor over and above the T stage in 
head and neck cancer. However, data from the Indian 
subcontinent is sparse, even more so in patients treated by 
IMRT. This merits further study owing to possible differences 
in the biology of Indian head and neck cancer compared to its 
western counterpart. Ours was a prospective study that 
attempted to elucidate the role of tumor volume as a 
prognostic factor in locally advanced oropharyngeal and 
hypopharyngeal cancer. 
 
Material and Methods: We enrolled 87 patients of Stage III-IV 
squamous cell cancer of the hypopharynx(30), and 
oropharynx(57), who subsequently received definitive 
concurrent chemo radiation with IG-IMRT. The tumor volume 
was the gross tumor volume (TV) delineated on the planning 
CT scan and was calculated by the volume algorithm in the 
treatment planning system. The impact of TV on Locoregional 
relapse free survival (LRFS), Response to chemo radiation 
(RR), overall survival (OS),local control(LC) and regional 
control was assessed over a follow up of 2 years. The Shapiro 
wilk test was done for assessing normality. Survival analysis 
was by kaplan meir method with log rank testing for assessing 
significance between groups Univariate analysis was done by 
mann-whitney/chi square/fisher's exact test , multiariate 
analysis was done by logistic regression forward stepwise 
method and a model to predict LC was generated .An ROC 
curve analysis was done for estimation of cut offs.  
 
Results: The 2 year OS, LRFS, RR, LC& RC were 64%, 56%, 
65%,63% and 83% respectively .The T stage distribution was 
T2, T3&T4 (5/41/41).The TV was not normally distributed 
and the mean TV was 48 cc (5-167cc) with mean TV in T3 /T4 
patients of 39.9/60.9 cc. The mean TV in locally controlled 
patients was 35.4cc vs 70.8cc in uncontrolled patients .While 
the TV was a significant prognostic predictor for the OS , 
LRFS ,RR, and LC on univariate analysis , on the multivariate 
analysis only the TV predicted for LC. ROC curve analysis 
found cut off of 38 cc with 2 year LC of 84 % / 40% for 
TV<38cc / >38cc respectively with log rank p=0.001 with AUC 
of 0.759(0.653-0.865) and sensitivity/specificity of 82%/64%. 
ROC curve analysis of our oropharyngeal subgroup revealed 
similar results with a cut off of 38cc with AUC of 0.770 
(0.644-0.896) and sensitivity / specificity of 80%/66%.with 2 
year LC of 79%/30% for TV<38cc / >38cc (p=0.001). The 
likelihood of local failure increased by 3 % for 1cc increase in 
TV for the entire cohort & 3% for our oropharyngeal 
subgroup. 
 
 
 
Conclusion: TV is an independent prognostic factor in 
patients with head and neck cancer in predicting local 
control. Implications for existing management paradigms 
include, stratification according to TV in future randomized 
trials, consideration of altered fractionation and/or dose 
escalation to the primary disease for patients with TV>38cc.  
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Purpose or Objective: With increasing evidence for 
combined modality treatment in locally advanced squamous 
cell cancer of the head and neck (HNSCC), there remains 
debate about the best treatment approach for patients with 
T4 disease. Local control in HNSCC is extremely important 
due to the morbidity and mortality associated with local 
recurrence. However treatment itself can be associated with 
significant morbidity. The purpose of this review is to 
determine both overall survival (OS) and local control rates 
for patients with T4 tumours treated with Intensity 
Modulated Radiotherapy (IMRT) with or without prior surgery. 
